What is Paracrine Communication?
Paracrine signaling is communication between cells that are close together. One cell releases a signaling molecule, the molecule diffuses a short distance through the fluid and matrix between cells, and nearby cells that carry a matching receptor respond. Paracrine signals usually act quickly and briefly: the molecules are broken down by enzymes or taken up by neighbouring cells soon after release, which keeps the effect local.[1]
The idea matters in stem cell medicine because transplanted cells are now thought to act largely through the signals they release rather than by turning into new tissue. That idea, the paracrine hypothesis, is set out below; the full set of molecules a cell releases is described on our page on the secretome.
Paracrine, Autocrine, Juxtacrine and Endocrine Signaling Compared
Cells signal to each other in four main ways, which differ in how far the signal travels and whether it needs to leave the cell at all.[1]
| Type | Target | How the signal travels | Example |
|---|---|---|---|
| Autocrine | The cell that released the signal, or neighbouring cells of the same type | Released and bound by receptors on the releasing cell | A virus-infected cell signalling itself to undergo programmed cell death;[1] prostaglandins, which act on the cells that make them as well as on neighbours[2] |
| Paracrine | Nearby cells | Diffuses a short distance; high local concentration, quickly removed | Neurotransmitters crossing the 20 to 40 nanometre gap of a synapse[1] |
| Juxtacrine (contact-dependent) | A cell touching the signalling cell | Not released: the signal stays on the surface of one cell and binds a receptor on the other | Delta or Jagged on one cell activating the Notch receptor on its neighbour[3] |
| Endocrine | Distant cells anywhere in the body | Hormones carried in the bloodstream; slower, longer-lasting, low concentration at the target | Hormones of the thyroid, pituitary and other endocrine glands[1] |
Two related terms are sometimes added to this list. Cells joined by gap junctions pass ions such as calcium and other small molecules directly from one cell’s interior to the next.[1] Exocrine glands are not a form of cell signaling: they release secretions such as sweat, saliva, mucus and milk through ducts onto an epithelial surface, whereas endocrine glands, such as the anterior pituitary, thymus, adrenal cortex and gonads, release hormones that reach their targets through the bloodstream.[4]
The categories overlap. The same molecule can work in more than one way: growth factors that bind the epidermal growth factor receptor are made as membrane-anchored precursors that can signal to a touching cell, and after being cut free they can act in an autocrine, paracrine or even endocrine way.[5] Cytokines likewise act on the cell that released them, on nearby cells or, sometimes, on distant cells; they are covered on our page on immunomodulation.
Examples of Paracrine Signaling
- Synapses. At a chemical synapse, a nerve cell releases neurotransmitters that cross the narrow gap to the next cell; enzymes break some of them down or the releasing cell takes them back up, so the next cell can respond again quickly.[1]
- Wound healing. In healing mouse skin wounds, the gene for keratinocyte growth factor, a member of the fibroblast growth factor (FGF) family, was switched on 160-fold, mainly in the deeper skin layer, while its receptor was found mainly in the outer layer, suggesting that the factor made in the dermis stimulates the surface skin cells.[6]
- Blood vessel growth. Vascular endothelial growth factor A (VEGF-A) is a key regulator of normal and disease-related angiogenesis, the growth of new vessels from existing ones. Blocking it became a treatment: the antibody bevacizumab was approved in the United States in 2004 for metastatic colorectal cancer, and VEGF-A inhibitors were approved for eye disease in 2004 and 2006.[7]
- Prostaglandins. These lipid mediators, made from arachidonic acid by the cyclooxygenase enzymes, act as autocrine and paracrine signals that maintain local balance and change sharply during inflammation.[2] Non-steroidal anti-inflammatory drugs block their production.[8]
Notch: Signaling by Direct Contact
Notch signaling is the standard example of juxtacrine, not paracrine, signaling. The Notch receptor is activated when it binds a ligand of the Delta or Jagged (Serrate) family presented on the surface of a neighbouring cell. Binding leads to cuts in the receptor that release its inner part, which moves to the nucleus and joins a DNA-bound protein to switch genes on. Each receptor molecule is activated once, without a chain of amplifying messengers. Notch controls many steps of development and tissue renewal, and faults in the pathway underlie developmental syndromes, adult-onset diseases and cancers.[3]
Why is paracrine signaling important?
Local signaling lets a tissue respond to a change in one place without affecting the whole body: a wound edge, an inflamed joint or a growing blood vessel. It is also central to how mesenchymal stromal cells (MSCs), the cells used in many experimental stem cell therapies, are thought to work.
The paracrine hypothesis. MSCs can form bone, cartilage and fat cells, but they also secrete growth factors and cytokines that, in laboratory and animal studies, damp down local immune responses, reduce scarring and cell death, encourage blood vessel growth and stimulate the tissue’s own repair cells; these “trophic” effects are distinct from the cells turning into new tissue.[9] In many animal and early human studies of heart attack, too few transplanted cells survived and became heart or vessel cells to explain the improvement reported, so researchers proposed that factors released by the cells were responsible.[10] Factors that have been named include:
| Factor | Observed effect | Evidence |
|---|---|---|
| VEGF, basic FGF, HGF, IGF-1 | Released by MSCs, several in larger amounts in low oxygen; MSC conditioned medium made blood vessel cells multiply and migrate and improved blood flow in an ischaemic limb[10][11] | Human cells in the laboratory; mice |
| TGF-beta1 and HGF | MSCs suppressed T cell proliferation without touching the T cells; antibodies to these two factors reversed it[12] | Human cells in the laboratory |
| Prostaglandin E2 (PGE2) | In mice with sepsis, MSCs made the animals’ macrophages produce more interleukin-10 through PGE2, and survival improved[13] | Mice |
| TSG-6 | Released by MSCs trapped in the lungs after infusion; it reduced inflammation and heart attack size[14] | Mice |
| Extracellular vesicles | Purified 50 to 100 nanometre vesicles from MSCs reduced infarct size[15] | Mice |
Vesicles as a separate fraction are covered on our page on exosomes and extracellular vesicles, the way infused cells reach or fail to reach tissues on our page on homing and cell migration, and the signals that steer cell movement on our page on chemokines.
Human tissue supports the “short stay” part of the idea: in autopsies of patients treated with donor MSCs, little donor material was found, and the small amounts of donor DNA detected did not relate to whether patients had responded[16] (the numbers are on our page on homing and cell migration). Whether paracrine effects help patients is a separate question, and for MSCs the answer from advanced trials has so far been disappointing.[17] The one MSC product approved in the United States, remestemcel-L (Ryoncil), is for children aged 2 months and older with acute graft-versus-host disease that has not responded to steroids;[18] it is described on our page on immunomodulation. The wider field is described on our regenerative medicine page.
Published Clinical Citations
[1] ^ Clark MA, Douglas M, Choi J. Biology 2e. Section 9.1, Signaling Molecules and Cellular Receptors. OpenStax; 2018. https://openstax.org/books/biology-2e/pages/9-1-signaling-molecules-and-cellular-receptors
[2] ^ Ricciotti E, FitzGerald GA. Prostaglandins and inflammation. Arteriosclerosis, Thrombosis, and Vascular Biology. 2011;31(5):986-1000. https://doi.org/10.1161/ATVBAHA.110.207449
[3] ^ Kopan R, Ilagan MX. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell. 2009;137(2):216-233. https://doi.org/10.1016/j.cell.2009.03.045
[4] ^ Betts JG, Young KA, Wise JA, et al. Anatomy and Physiology 2e. Section 4.2, Epithelial Tissue. OpenStax; 2022. https://openstax.org/books/anatomy-and-physiology-2e/pages/4-2-epithelial-tissue
[5] ^ Singh AB, Harris RC. Autocrine, paracrine and juxtacrine signaling by EGFR ligands. Cellular Signalling. 2005;17(10):1183-1193. https://doi.org/10.1016/j.cellsig.2005.03.026
[6] ^ Werner S, Peters KG, Longaker MT, Fuller-Pace F, Banda MJ, Williams LT. Large induction of keratinocyte growth factor expression in the dermis during wound healing. Proceedings of the National Academy of Sciences of the USA. 1992;89(15):6896-6900. https://doi.org/10.1073/pnas.89.15.6896
[7] ^ Ferrara N, Adamis AP. Ten years of anti-vascular endothelial growth factor therapy. Nature Reviews Drug Discovery. 2016;15(6):385-403. https://doi.org/10.1038/nrd.2015.17
[8] ^ Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science. 2001;294(5548):1871-1875. https://doi.org/10.1126/science.294.5548.1871
[9] ^ Caplan AI, Dennis JE. Mesenchymal stem cells as trophic mediators. Journal of Cellular Biochemistry. 2006;98(5):1076-1084. https://doi.org/10.1002/jcb.20886
[10] ^ Gnecchi M, Zhang Z, Ni A, Dzau VJ. Paracrine mechanisms in adult stem cell signaling and therapy. Circulation Research. 2008;103(11):1204-1219. https://doi.org/10.1161/CIRCRESAHA.108.176826
[11] ^ Kinnaird T, Stabile E, Burnett MS, et al. Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circulation Research. 2004;94(5):678-685. https://doi.org/10.1161/01.RES.0000118601.37875.AC
[12] ^ Di Nicola M, Carlo-Stella C, Magni M, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood. 2002;99(10):3838-3843. https://doi.org/10.1182/blood.v99.10.3838
[13] ^ Németh K, Leelahavanichkul A, Yuen PS, et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E2-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nature Medicine. 2009;15(1):42-49. https://doi.org/10.1038/nm.1905
[14] ^ Lee RH, Pulin AA, Seo MJ, et al. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell. 2009;5(1):54-63. https://doi.org/10.1016/j.stem.2009.05.003
[15] ^ Lai RC, Arslan F, Lee MM, et al. Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury. Stem Cell Research. 2010;4(3):214-222. https://doi.org/10.1016/j.scr.2009.12.003
[16] ^ von Bahr L, Batsis I, Moll G, et al. Analysis of tissues following mesenchymal stromal cell therapy in humans indicates limited long-term engraftment and no ectopic tissue formation. Stem Cells. 2012;30(7):1575-1578. https://doi.org/10.1002/stem.1118
[17] ^ Galipeau J, Sensébé L. Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. Cell Stem Cell. 2018;22(6):824-833. https://doi.org/10.1016/j.stem.2018.05.004
[18] ^ Mesoblast, Inc. RYONCIL (remestemcel-L-rknd). US prescribing information. DailyMed set ID a4e0918f-7444-4694-adeb-d38d98345659. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a4e0918f-7444-4694-adeb-d38d98345659